Rein therapeutics announces first patient dosed in renew phase 2 trial of lti-03 in patients with ipf

Trial is evaluating the safety, tolerability, and efficacy of lti-03 in idiopathic pulmonary fibrosis (ipf) with topline interim data expected in the first half of 2026 austin, texas , may 27, 2025 /prnewswire/ -- rein therapeutics ("rein") (nasdaq: rntx), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced today that the first patient has been dosed in the renew phase 2 trial of its lead asset, lti-03, a novel, multi-pathway, caveolin-1-related peptide for the treatment of ipf. "we are pleased to have dosed the first patient in our renew phase 2 trial of lti-03 following initiation of the trial.
IQV Ratings Summary
IQV Quant Ranking